Atricure reports second quarter 2023 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced second quarter 2023 financial results. “we are proud to report an exceptional quarter at atricure, highlighted by robust worldwide growth and meaningful operating leverage. our performance showcases the breadth of opportunities that exist in our business and.
ATRC Ratings Summary
ATRC Quant Ranking